Key result
Valdecoxib was withdrawn from the market in 2005 due to an increased risk of cardiovascular thrombotic events and unpredictable, potentially life-threatening skin reactions.
Answers are grounded in this paper and cite their sources.
Valdecoxib, a COX-2 inhibitor, was withdrawn from the market in 2005 due to cardiovascular and dermatological safety concerns despite its reduced gastrointestinal complications.
INTRODUCTION: Valdecoxib is a cyclooxygenase-2 (COX-2) selective anti-inflammatory drug. It is associated with a reduced incidence of gastrointestinal complications and is potentially useful for patients with rheumatological diseases requiring longer term anti-inflammatory treatment. AREAS COVERED: Due to a perceived increased risk of thrombotic events, particularly cardiovascular hazards and reports of unpredictable, potentially life threatening skin reactions, valdecoxib has been voluntarily withdrawn from the market since 2005. This review manuscript examines the therapeutic potential and the adverse events of valdecoxib utilising a pubmed and web of sciences search to select literature on this subject. EXPERT OPINION: While valdecoxib did have reduced incidence of gastrointestinal complications due to a perceived increased risk of thrombotic events it was withdrawn. The limitations of the research supporting the withdrawal of this potential are discussed.
No takes yet. Share an insight, caveat, or question.
Atukorala et al. (2013) conducted a review in Rheumatological diseases. Valdecoxib was evaluated. Valdecoxib was withdrawn from the market in 2005 due to an increased risk of cardiovascular thrombotic events and unpredictable, potentially life-threatening skin reactions.
Synapse has enriched 10 related papers. Consider them for comparative context: